Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q2 FY24 results · Jul–Sep 2023
Lincoln Pharmaceuticals reported revenue from operations of ₹155.99 crore (up 10.9% from Q2 FY23) and net profit of ₹27.65 crore (up 16.6% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 155.99 | 140.61 | +10.9% | 135.62 | +15.0% |
| Other income | 8.69 | 5.72 | +52.0% | 7.69 | +13.1% |
| Total income | 164.68 | 146.33 | +12.5% | 143.31 | +14.9% |
| Profit before tax | 36.87 | 32.06 | +15.0% | 25.45 | +44.9% |
| Net profit for the period | 27.65 | 23.71 | +16.6% | 19.01 | +45.4% |
| EPS, basic (₹) | 13.81 | 11.84 | +16.6% | 9.49 | +45.5% |
| Net margin (%) | 17.7 | 16.9 | 14.0 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 155.99 | 140.61 | +10.9% | 135.62 | +15.0% |
| Other income | 8.69 | 5.69 | +52.9% | 7.69 | +13.1% |
| Total income | 164.68 | 146.30 | +12.6% | 143.31 | +14.9% |
| Profit before tax | 36.87 | 32.03 | +15.1% | 25.45 | +44.9% |
| Net profit for the period | 27.65 | 23.71 | +16.6% | 19.01 | +45.4% |
| EPS, basic (₹) | 13.81 | 11.84 | +16.6% | 9.49 | +45.5% |
| Net margin (%) | 17.7 | 16.9 | 14.0 |
Consolidated
- Filed with BSE
- 17 Nov 2023, 15:12 IST
- Board meeting
- 02 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Nov 2023, 15:12 IST
- Board meeting
- 02 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE